BIOMARKERS IN OBESITY-RELATED METABOLIC SYNDROME: FROM PATHOPHYSIOLOGY TO CLINICAL APPLICATION
Biomarkers and obesity related metabolic syndrome
Abstract
Obesity-related metabolic syndrome (MetS) represents a complex, multifactorial disorder characterized by central obesity, insulin resistance, dyslipidemia, hypertension, and chronic low-grade inflammation. Its rising global prevalence underscores the urgent need for comprehensive understanding and early detection strategies. While traditional clinical and biochemical parameters provide insight into overt metabolic dysfunction, they often fail to capture upstream molecular disturbances.
Recent research has identified a spectrum of novel biomarkers that reflect the pathophysiological mechanisms underlying MetS, including inflammatory mediators (high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, plasminogen activator inhibitor-1), adipokines and hormonal regulators (adiponectin, leptin, resistin, visfatin, ghrelin, glucagon-like peptide-1), oxidative stress and endothelial dysfunction markers (malondialdehyde, 8-isoprostane, oxidized LDL, asymmetric dimethylarginine, paraoxonase-1), thyroid function indicators (TSH, free thyroxine, anti-thyroid peroxidase antibodies), vitamin D, and genetic/epigenetic modulators (microRNAs and DNA methylation patterns).
This review summarizes current evidence on these biomarkers, highlighting their roles in elucidating disease mechanisms, enabling early risk assessment, guiding therapeutic interventions, and supporting precision medicine approaches. Future research directions are proposed to standardize assays, validate findings across diverse populations, and develop integrated multi-marker panels to optimize the management of obesity-related MetS.
Key words: Obesity, Metabolic syndrome, Adipokines, Inflammation, Insulin resistance,
References
Options, Emerging Biological Mechanisms, Future Perspectives and Challenges. Diabetes
Metab Syndr Obes. 2025;18:3427-3445. doi: 10.2147/DMSO.S540103
2. Swarup S, Ahmed I, Grigorova Y, et al. Metabolic Syndrome. [Updated 2024 Mar 7]. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK459248/
3.Kucher SV, Mudra UO, Tkachuk VV, Ruda MM, Chernets TY, Nikitina IM, Dzhyvak VH.
Impact of lifestyle modification interventions on metabolic syndrome and obesity in adults.
Wiad Lek. 2025;78(9):1857-1865. doi: 10.36740/WLek/212515.
4. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020.
5. Oladipupo SO, Ezenabor EH, Ojo AB, Ogunlakin AD, Ojo OA. Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health. Obesity Medicine. 2025:100613.
6. Decarie-Spain L, Kanoski SE. Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward. Nutrients. 2021;13(3):977. doi: 10.3390/nu13030977.
7. Patial R, Batta I, Thakur M, Sobti RC, Agrawal DK. Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome. Arch Intern Med Res. 2024;7(4):273-283. doi: 10.26502/aimr.0184.
8. Islam MS, Wei P, Suzauddula M, Nime I, Feroz F, Acharjee M, Pan F. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med. 2024 Dec 27;30(1):279. doi: 10.1186/s10020-024-01019-y.
9. Morgado F, Valado A, Metello J, Pereira L. Laboratory markers of metabolic syndrome. Explor Cardiol. 2024;2:114–33. https://doi.org/10.37349/ec.2024.00026
10. Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020 Feb 25;7:22. doi: 10.3389/fcvm.2020.00022.
11. Thomaz FS, John OD, Sinha P, Shafie SR, Worrall S. The Metabolic Syndrome: An Overview and Proposed Mechanisms. Obesities. 2024;4(3):226-255. https://doi.org/10.3390/obesities4030020
12. Aida X MU, Ivan TV, Juan G JR. Adipose Tissue Immunometabolism: Unveiling the Intersection of Metabolic and Immune Regulation. Rev Invest Clin. 2024;76(2):65-79. doi: 10.24875/RIC.23000231.
13. Yang ZH, Chen FZ, Zhang YX, Ou MY, Tan PC, Xu XW, Li QF, Zhou SB. Therapeutic targeting of white adipose tissue metabolic dysfunction in obesity: mechanisms and opportunities. MedComm (2020). 2024;5(6):e560. doi: 10.1002/mco2.560.
14. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci. 2023;24(9):7898. doi: 10.3390/ijms24097898.
15. Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The Role of Adipokines in Inflammatory Mechanisms of Obesity. Int J Mol Sci. 2022;23(23):14982. doi: 10.3390/ijms232314982.
16. Schleh MW, Caslin HL, Garcia JN, Mashayekhi M, Srivastava G, Bradley AB, Hasty AH. Metaflammation in obesity and its therapeutic targeting. Sci Transl Med. 2023;15(723):eadf9382. doi: 10.1126/scitranslmed.adf9382. Epub 2023 Nov 22.
17. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29(8):439-93.
18. Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, Davis RJ. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci U S A. 2020;117(6):2751-2760. doi: 10.1073/pnas.1920004117.
19. Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nat Metab. 2021;3(10):1302-1312. doi: 10.1038/s42255-021-00470-z. Epub 2021 Oct 14.
20. Li X, Ren Y, Chang K, Wu W, Griffiths HR, Lu S, Gao D. Adipose tissue macrophages as potential targets for obesity and metabolic diseases. Front Immunol. 2023;14:1153915. doi: 10.3389/fimmu.2023.1153915.
21. Wang L, Chen L, Liu Z, Liu Y, Luo M, Chen N, Deng X, Luo Y, He J, Zhang L, Hill MA, Li R, Wu J. PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity. Front Pharmacol. 2018;9:1087. doi: 10.3389/fphar.2018.01087.
22. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, Laborde-Cárdenas CC, Tornero-Aguilera JF. The Role of Adipokines in Health and Disease. Biomedicines. 2023;11(5):1290. doi: 10.3390/biomedicines11051290.
23. Ramakrishnan N, Auger K, Rahimi N, et al. Biochemistry, Adiponectin. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537041/
24. Hu W, Zhu H, Gong F. Leptin and leptin resistance in obesity: current evidence, mechanisms and future directions. Endocr Connect. 2025;14(9):e250521. doi: 10.1530/EC-25-0521.
25. Li Y, Yang Q, Cai D, Guo H, Fang J, Cui H, Gou L, Deng J, Wang Z, Zuo Z. Resistin, a Novel Host Defense Peptide of Innate Immunity. Front Immunol. 2021;12:699807. doi: 10.3389/fimmu.2021.699807.
